GRAIL is trading 14.65% up now at $92.60, with the strongest catalyst appearing to be the FDA advisory committee meeting scheduled for September 23, 2026, to review Galleri’s premarket approval application.
- Second-quarter revenue was $44.7 million, while a $110 million Samsung financing agreement reinforced commercial-expansion expectations.
- Broader risk-on sentiment may provide additional support, with major U.S. indices higher pre-market.